Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT06867510Phase 3Not yet recruiting
A Phase 3 trial of bupivacaine hydrochloride 0.75% injection in postoperative pain, sponsored by Tanta University. Planned start Apr 2025; status: not yet recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT06867510.